Drugs used for their effects on the respiratory system.
Drugs that act principally at one or more sites within the peripheral neuroeffector systems, the autonomic system, and motor nerve-skeletal system. (From Smith and Reynard, Textbook of Pharmacology, 1991, p75)
The tubular and cavernous organs and structures, by means of which pulmonary ventilation and gas exchange between ambient air and the blood are brought about.
Drugs that act on neuronal sensory receptors resulting in an increase, decrease, or modification of afferent nerve activity. (From Smith and Reynard, Textbook of Pharmacology, 1991, p367)
A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)
The capability of the LUNGS to distend under pressure as measured by pulmonary volume change per unit pressure change. While not a complete description of the pressure-volume properties of the lung, it is nevertheless useful in practice as a measure of the comparative stiffness of the lung. (From Best & Taylor's Physiological Basis of Medical Practice, 12th ed, p562)
The physical or mechanical action of the LUNGS; DIAPHRAGM; RIBS; and CHEST WALL during respiration. It includes airflow, lung volume, neural and reflex controls, mechanoreceptors, breathing patterns, etc.
Physiological processes and properties of the RESPIRATORY SYSTEM as a whole or of any of its parts.
Physiologically, the opposition to flow of air caused by the forces of friction. As a part of pulmonary function testing, it is the ratio of driving pressure to the rate of air flow.
Congenital structural abnormalities of the respiratory system.
Measurement of the amount of air that the lungs may contain at various points in the respiratory cycle.
The volume of air remaining in the LUNGS at the end of a normal, quiet expiration. It is the sum of the RESIDUAL VOLUME and the EXPIRATORY RESERVE VOLUME. Common abbreviation is FRC.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
The volume of air inspired or expired during each normal, quiet respiratory cycle. Common abbreviations are TV or V with subscript T.
The act of breathing with the LUNGS, consisting of INHALATION, or the taking into the lungs of the ambient air, and of EXHALATION, or the expelling of the modified air which contains more CARBON DIOXIDE than the air taken in (Blakiston's Gould Medical Dictionary, 4th ed.). This does not include tissue respiration (= OXYGEN CONSUMPTION) or cell respiration (= CELL RESPIRATION).
Thin-walled sacs or spaces which function as a part of the respiratory system in birds, fishes, insects, and mammals.
Any method of artificial breathing that employs mechanical or non-mechanical means to force the air into and out of the lungs. Artificial respiration or ventilation is used in individuals who have stopped breathing or have RESPIRATORY INSUFFICIENCY to increase their intake of oxygen (O2) and excretion of carbon dioxide (CO2).
The force per unit area that the air exerts on any surface in contact with it. Primarily used for articles pertaining to air pressure within a closed environment.
The measurement of frequency or oscillation changes.
Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.
A method of mechanical ventilation in which pressure is maintained to increase the volume of gas remaining in the lungs at the end of expiration, thus reducing the shunting of blood through the lungs and improving gas exchange.
The total volume of gas inspired or expired per unit of time, usually measured in liters per minute.
Respiratory tract diseases are a broad range of medical conditions that affect the nose, throat, windpipe, and lungs, impairing breathing and oxygen uptake, including asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, influenza, tuberculosis, and sleep apnea.
Measurement of volume of air inhaled or exhaled by the lung.
A species of migratory Old World locusts, in the family ACRIDIDAE, that are important pests in Africa and Asia.
The exchange of OXYGEN and CARBON DIOXIDE between alveolar air and pulmonary capillary blood that occurs across the BLOOD-AIR BARRIER.
A highly toxic gas that has been used as a chemical warfare agent. It is an insidious poison as it is not irritating immediately, even when fatal concentrations are inhaled. (From The Merck Index, 11th ed, p7304)
Chemicals that are used to cause the disturbance, disease, or death of humans during WARFARE.
Severe irritant and vesicant of skin, eyes, and lungs. It may cause blindness and lethal lung edema and was formerly used as a war gas. The substance has been proposed as a cytostatic and for treatment of psoriasis. It has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP-85-002, 1985) (Merck, 11th ed).
Tactical warfare using incendiary mixtures, smokes, or irritant, burning, or asphyxiating gases.
Compounds that contain the radical R2C=N.OH derived from condensation of ALDEHYDES or KETONES with HYDROXYLAMINE. Members of this group are CHOLINESTERASE REACTIVATORS.
A group of methane-based halogenated hydrocarbons containing one or more fluorine and chlorine atoms.
Visible accumulations of fluid within or beneath the epidermis.

Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. (1/112)

This 6-month, randomized, multicenter study was designed to determine whether patients who had been treated with the leukotriene pathway inhibitor zileuton 600 mg four times daily (QID) for 2 months could be maintained at the same level of pulmonary function, symptom control, and beta-agonist use with less frequent dosing--first 600 or 800 mg three times daily (TID) and then twice daily (BID). A total of 278 patients with chronic asthma, ages 16 to 70, participated at 25 US centers. All had a 1-second forced expiratory volume (FEV1) of 35%-75%, reversible airway disease, and a nonsmoking history of 1 year. An 8-week open-label period (zileuton 600 mg QID) was followed by a 16-week double-blind period, in which patients who responded to the QID treatment were randomized to receive zileuton 600 or 800 mg TID for 8 weeks and then rerandomized to receive zileuton 600 or 800 mg BID for another 8 weeks. Primary outcomes were FEV1 and asthma symptom scores; secondary outcomes were peak expiratory flow rate, beta-agonist use, and asthma exacerbations requiring steroid rescue. Patients who showed improvements in lung function when treated with zileuton 600 mg QID demonstrated minimal decreases in FEV1 and comparable peak expiratory flow rates, symptom control, beta-agonist use, and systemic corticosteroid rescue when being treated with lower doses and/or less frequent doses of zileuton. Patients who demonstrate improved asthma control with zileuton 600 mg QID may be able to reduce their daily dosage and/or frequency while still maintaining the same level of symptom control.  (+info)

Inhaled NO and almitrine bismesylate in patients with acute respiratory distress syndrome: effect of noradrenalin. (2/112)

The combination of inhaled nitric oxide with almitrine bismesylate has been proposed for the management of acute respiratory distress syndrome in order to divert pulmonary blood flow away from poorly ventilated toward well-ventilated areas. The aims of this prospective and comparative study were to: 1) confirm the beneficial effects on oxygenation of this association; 2) evaluate the haemodynamic effects of this association; and 3) evaluate the influence of noradrenaline (a nonspecific vasoconstrictor) on the modification of gas exchange related to inhaled NO and/or almitrine bismesylate. Forty-one sedated paralysed and ventilated patients were investigated. Haemodynamic and blood gas measurements were performed in a fixed order: baseline; inhalation of NO for 30 min.; intravenous infusion of almitrine bismesylate; and concomitant administration of inhaled NO and almitrine bismesylate. Inhaled NO and almitrine bismesylate increased arterial oxygen tension (Pa,O2)/inspiratory oxygen fraction (FI,O2) (p<0.001). The association of inhaled NO with almitrine bismesylate resulted in a dramatic improvement in Pa,O2/FI,O2 (p<0.0001 versus almitrine bismesylate, p<0.05 versus inhaled NO). In patients receiving noradrenalin (n = 19), almitrine bismesylate had no effect on oxygenation. The present study confirmed that the combination of inhaled NO with almitrine bismesylate improved oxygenation, and demonstrated that almitrine bismesylate has no effect on oxygenation in patients receiving noradrenalin.  (+info)

Idiopathic pulmonary fibrosis in infants: good prognosis with conservative management. (3/112)

BACKGROUND: Pulmonary interstitial fibrosis in children is a disease of unknown aetiology, usually associated with a poor prognosis. METHODS: In this case series we describe 11 children presenting over a 10 year period, managed conservatively and associated with a good prognosis. RESULTS: In six, symptoms were present from birth and 10 had symptoms at or before 3 months. Diagnosis was made using chest computed tomography and percutaneous lung biopsy. All patients were treated with oral prednisolone. In five no steroid response was noted. One patient responded to hydroxychloroquine. Home oxygen was required in five patients. At follow up all patients are alive at a median age of 6 years (range 1 to 12 years). The two recently diagnosed children have significant symptoms, seven have dyspnoea on exercise, and two are symptom free. CONCLUSION: The good prognosis seen in these patients is different to previous case reports, indicating a greater than 50% mortality.  (+info)

Effect of inhaled prostacyclin in combination with almitrine on ventilation-perfusion distributions in experimental lung injury. (4/112)

BACKGROUND: Inhaled prostacyclin and intravenous almitrine have both been shown to improve pulmonary gas exchange in acute lung injury (ALI). This study was performed to investigate a possible additive effect of prostacyclin and almitrine on pulmonary ventilation-perfusion (VA/Q) ratio in ALI compared with inhaled prostacyclin or intravenous almitrine alone. METHODS: Experimental ALI was established in 24 pigs by repeated lung lavage. Animals were randomly assigned to receive either 25 ng.kg(-1).min(-1) inhaled prostacyclin alone, 1 microg.kg(-1).min(-1) almitrine alone, 25 ng.kg(-1).min(-1) inhaled prostacyclin in combination with 1 microg.kg(-1).min(-1) almitrine, or no specific treatment (controls) for 30 min. For each intervention, pulmonary gas exchange and hemodynamics were analyzed and VA/Q distributions were calculated using the multiple inert gas elimination technique. The data was analyzed within and between the groups by analysis of variance for repeated measurements, followed by the Student-Newman-Keuls test for multiple comparison when analysis of variance revealed significant differences. RESULTS: All values are expressed as mean +/- SD. In controls, pulmonary gas exchange, hemodynamics, and VA/Q distribution remained unchanged. With prostacyclin alone and almitrine alone, arterial oxygen partial pressure (PaO2) increased, whereas intrapulmonary shunt (QS/QT) decreased (P < 0.05). Combined prostacyclin and almitrine also increased PaO2 and decreased QS/QT (P < 0.05). When compared with either prostacyclin or almitrine alone, the combined application of both drugs revealed no additional effect in gas exchange or VA/Q distribution. CONCLUSIONS: The authors conclude that, in this experimental model of ALI, the combination of 25 ng.kg(-1).min(-1) prostacyclin and 1 microg.kg(-1).min(-1) almitrine does not result in an additive improvement of pulmonary gas exchange or VA/Q distribution when compared with prostacyclin or almitrine alone.  (+info)

Ultrasound measurements of fetal breathing movements in the rat. (5/112)

The goal of this study was to determine when fetal breathing movements (FBMs) commence in the rat and to characterize age-dependent changes of FBMs in utero. These data provide a frame of reference for parallel in vitro studies of the cellular, synaptic, and network properties of the perinatal rat respiratory system. Ultrasound recordings were made from unanesthetized Sprague-Dawley rats from embryonic (E) day 15 (E15) to E20. Furthermore, the effects of respiratory stimulants (doxapram and aminophylline) and hypoxia on FBMs were studied. Single FBMs, occurring at a very low frequency (approximately 8 FBMs/h), commenced at E16. The incidence of single FBMs increased to approximately 80 FBMs/h by E20. Episodes of clustered rhythmic FBMs were first observed at E18 (approximately 40 FBMs/h). The incidence of episodic clustered FBMs increased to approximately 300 FMBs/h by E20, with the duration of each episode ranging from approximately 40 to 180 s. Doxapram, presumably acting to stimulate carotid body receptors, did not increase FBMs until E20, when the incidence of episodic clustered FBMs increased twofold. Aminophylline, a central-acting stimulant, caused an increase in episodic clustered FBMs after E17, reaching significance at E20 (3-fold increase). Exposing the dam to 10% O(2) caused a rapid, marked suppression of FBMs (5-fold decrease) that was readily reversed on exposure to room air.  (+info)

Association of oral almitrine and medroxyprogesterone acetate: effect on arterial blood gases in chronic obstructive pulmonary disease. (6/112)

Almitrine (A) and medroxyprogesterone acetate (MA) given separately improve arterial blood gases in some patients with chronic obstructive pulmonary disease (COPD); the aim of this study was to assess the effect of the two drugs given together. Forty-eight patients with irreversible COPD and hypoxaemia were prospectively enrolled into a 14-day run-in period and received single-blind oral treatment with double placebo. Patients whose PaO2 remained stable (less than 10% change; n = 29, 25 males, mean age 65.6 years) were included in a 14-day active treatment period and randomly assigned to three groups. They received double-blind oral treatment with: A (50 mg bid, group A, n = 10); MA (20 mg tid, group MA, n = 9); A (50 mg bid) and MA (20 mg tid, group A+MA, n = 10). Anthropometric and spirometric measurements were similar in the three groups and so were the arterial blood gas values at the beginning and the end of the run-in period. At the end of the active treatment period, blood gas changes (mean+/-SE) were significantly different between groups (P<0.05, Kruskal-Wallis test), with improvement in both hypoxaemia and hypercapnia in group A+MA only: delta PaO2 = 7.4+/-1.9 mmHg, delta PaCO2 = -5.1+/-1.7 m mHg (P<0.05, Wilcoxon test). In short-term treatment, the association of A and MA is more efficient than either drug alone at improving arterial blood gases in COPD patients.  (+info)

Changes in respiratory sensations induced by lobeline after human bilateral lung transplantation. (7/112)

1. The sensations evoked by the injection of lobeline into the right antecubital vein were studied in 8 subjects after bilateral lung transplantation and 10 control subjects. In control subjects, two distinct sensations were experienced. There was an early noxious sensation (onset approximately 10 s) followed by a late sensation of breathlessness (onset approximately 26 s) associated with involuntary hyperventilation. The early sensation was accompanied by respiratory and cardiovascular changes. 2. In contrast to control subjects, the early respiratory events and the noxious sensations evoked by injections of lobeline (18-60 microg kg(-1)) did not occur in subjects with recent bilateral lung transplantation. This suggests that the early respiratory sensations are mediated by the discharge of receptors in the lungs. 3. The late hyperventilation and the accompanying sensation of breathlessness occurred in both transplant and control subjects and are therefore likely to be mediated by receptors elsewhere in the body, presumably systemic arterial chemoreceptors stimulated by lobeline. 4. In control subjects, but not transplant subjects, there was a consistent decrease in mean arterial pressure associated with the lobeline injection. This suggests that pulmonary afferents mediate the hypotension. 5. For transplant subjects studied more than a year after transplantation, there was some evidence that the noxious respiratory sensations evoked by lobeline had returned. This suggests that some functional reinnervation of pulmonary afferents may occur.  (+info)

Flowmetric comparison of respiratory inductance plethysmography and pneumotachography in horses. (8/112)

Respiratory inductance plethysmographic (RIP) and pneumotachographic (Pn) flows were compared dynamically in horses with bronchoconstriction. On a breath-by-breath basis, RIP was normalized to inspiratory volume from Pn, and peak [peak of subtracted final exhalation waveform (SFE(max))] and selected area [integral of subtracted final waveform during first 25% of exhaled volume (SFE(int))] differences between RIP and Pn flows during early expiration were measured in three settings: 1) healthy horses (n = 8) undergoing histamine bronchoprovocation; 2) horses with naturally occurring lower airway obstruction (AO) (n = 7); and 3) healthy horses (n = 6) given lobeline. HCl to induce hyperpnea. In setting 1, histamine challenge induced a dose-dependent increase in SFE(max) and SFE(int) differences. A test index of airway reactivity (interpolated histamine dose that increased SFE(max) by 35%) closely correlated (r(s) = 0.93, P = 0.001) with a conventional index (histamine dose that induced a 35% decrease in dynamic compliance). In setting 2, in horses with AO, SFE(max) and SFE(int) were markedly elevated, and their absolute values correlated significantly (P < 0.005) with pulmonary resistance and the maximum change in transpulmonary pressure. The effects of bronchodilator treatment on the SFE(max) and SFE(int) were also highly significant (P < 0.0001). In setting 3, hyperpnea, but not tachypnea, caused significant (P < 0.01) increases in SFE(max) but not in SFE(int). In conclusion, dynamic comparisons between RIP and Pn provide a defensible method for quantifying AO during tidal breathing, without the need for invasive instrumentation.  (+info)

Respiratory system agents are substances that affect the respiratory system, which includes the nose, throat (pharynx), voice box (larynx), windpipe (trachea), bronchi, and lungs. These agents can be classified into different categories based on their effects:

1. Respiratory Stimulants: Agents that increase respiratory rate or depth by acting on the respiratory center in the brainstem.
2. Respiratory Depressants: Agents that decrease respiratory rate or depth, often as a side effect of their sedative or analgesic effects. Examples include opioids, benzodiazepines, and barbiturates.
3. Bronchodilators: Agents that widen the airways (bronchioles) in the lungs by relaxing the smooth muscle around them. They are used to treat asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Examples include albuterol, ipratropium, and theophylline.
4. Anti-inflammatory Agents: Agents that reduce inflammation in the airways, which can help relieve symptoms of asthma, COPD, and other respiratory conditions. Examples include corticosteroids, leukotriene modifiers, and mast cell stabilizers.
5. Antitussives: Agents that suppress coughing, often by numbing the throat or acting on the cough center in the brainstem. Examples include dextromethorphan and codeine.
6. Expectorants: Agents that help thin and loosen mucus in the airways, making it easier to cough up and clear. Examples include guaifenesin and iodinated glycerol.
7. Decongestants: Agents that narrow blood vessels in the nose and throat, which can help relieve nasal congestion and sinus pressure. Examples include pseudoephedrine and phenylephrine.
8. Antimicrobial Agents: Agents that kill or inhibit the growth of microorganisms such as bacteria, viruses, and fungi that can cause respiratory infections. Examples include antibiotics, antiviral drugs, and antifungal agents.

Peripheral nervous system (PNS) agents are a category of pharmaceutical drugs that act on the peripheral nervous system, which includes all the nerves outside the central nervous system (the brain and spinal cord). These agents can be further classified into various subgroups based on their specific mechanisms of action and therapeutic effects. Here are some examples:

1. Local anesthetics: These drugs block nerve impulses by inhibiting the sodium channels in the neuronal membrane, thereby preventing the generation and transmission of nerve impulses. They are commonly used to provide local or regional anesthesia during surgical procedures or to manage pain. Examples include lidocaine, bupivacaine, and prilocaine.
2. Neuropathic pain agents: These drugs are used to treat neuropathic pain, which is caused by damage or dysfunction of the peripheral nerves. They can act on various targets, including sodium channels, N-methyl-D-aspartate (NMDA) receptors, and voltage-gated calcium channels. Examples include gabapentin, pregabalin, duloxetine, and amitriptyline.
3. Muscle relaxants: These drugs act on the skeletal muscle to reduce muscle tone and spasticity. They can be classified into two main categories: centrally acting muscle relaxants (e.g., baclofen, tizanidine) and peripherally acting muscle relaxants (e.g., cyclobenzaprine, carisoprodol).
4. Cholinergic agents: These drugs act on the cholinergic receptors in the PNS to modulate nerve impulse transmission. They can be further classified into muscarinic and nicotinic agonists or antagonists, depending on their specific mechanism of action. Examples include neostigmine, pyridostigmine, and physostigmine.
5. Sympathomimetic agents: These drugs stimulate the sympathetic nervous system, which is part of the PNS that regulates the "fight or flight" response. They can be used to treat various conditions, such as hypotension, bronchospasm, and nasal congestion. Examples include epinephrine, norepinephrine, phenylephrine, and pseudoephedrine.
6. Sympatholytic agents: These drugs block the sympathetic nervous system to reduce its activity. They can be used to treat various conditions, such as hypertension, tachycardia, and anxiety. Examples include beta-blockers (e.g., propranolol, metoprolol), alpha-blockers (e.g., prazosin, doxazosin), and combined alpha-beta blockers (e.g., labetalol, carvedilol).
7. Neuropathic pain agents: These drugs are used to treat neuropathic pain, which is caused by damage or dysfunction of the nervous system. They can act on various targets in the PNS, such as sodium channels, N-methyl-D-aspartate (NMDA) receptors, and opioid receptors. Examples include lidocaine, capsaicin, tramadol, and tapentadol.
8. Antiepileptic drugs: These drugs are used to treat epilepsy, which is a neurological disorder characterized by recurrent seizures. They can act on various targets in the PNS, such as sodium channels, calcium channels, and GABA receptors. Examples include phenytoin, carbamazepine, valproate, lamotrigine, topiramate, and levetiracetam.
9. Antidepressant drugs: These drugs are used to treat depression, which is a mental disorder characterized by persistent low mood and loss of interest in activities. They can act on various targets in the PNS, such as serotonin receptors, norepinephrine receptors, and dopamine receptors. Examples include selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, sertraline), serotonin-norepinephrine reuptake inhibitors (SNRIs) (e.g., venlafaxine, duloxetine), tricyclic antidepressants (TCAs) (e.g., amitriptyline, imipramine), and monoamine oxidase inhibitors (MAOIs) (e.g., phenelzine, selegiline).
10. Antipsychotic drugs: These drugs are used to treat psychosis, which is a mental disorder characterized by hallucinations, delusions, and disordered thought processes. They can act on various targets in the PNS, such as dopamine receptors, serotonin receptors, and histamine receptors. Examples include typical antipsychotics (e.g., haloperidol, chlorpromazine) and atypical antipsychotics (e.g., clozapine, risperidone).
11. Anxiolytic drugs: These drugs are used to treat anxiety disorders, which are mental disorders characterized by excessive fear, worry, or nervousness. They can act on various targets in the PNS, such as GABA receptors and benzodiazepine receptors. Examples include benzodiazepines (e.g., diazepam, alprazolam), buspirone, and hydroxyzine.
12. Sedative drugs: These drugs are used to induce sleep or reduce excitement. They can act on various targets in the PNS, such as GABA receptors and histamine receptors. Examples include barbiturates (e.g., phenobarbital, secobarbital), benzodiazepines (e.g., diazepam, temazepam), and antihistamines (e.g., diphenhydramine, doxylamine).
13. Hypnotic drugs: These drugs are used to induce sleep. They can act on various targets in the PNS, such as GABA receptors and benzodiazepine receptors. Examples include benzodiazepines (e.g., triazolam, flunitrazepam) and non-benzodiazepine hypnotics (e.g., zolpidem, eszopiclone).
14. Antidepressant drugs: These drugs are used to treat depression, which is a mental disorder characterized by persistent feelings of sadness, hopelessness, or worthlessness. They can act on various targets in the PNS, such as serotonin receptors and norepinephrine transporters. Examples include selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline), tricyclic antidepressants (e.g., amitriptyline, imipramine), and monoamine oxidase inhibitors (e.g., phenelzine, selegiline).
15. Anxiolytic drugs: These drugs are used to reduce anxiety, which is a feeling of fear, worry, or unease. They can act on various targets in the PNS, such as GABA receptors and benzodiazepine receptors. Examples include benzodiazepines (e.g., alprazolam, lorazepam), buspirone, and hydroxyzine.
16. Antipsychotic drugs: These drugs are used to treat psychosis, which is a mental disorder characterized by hallucinations, delusions, or disordered thinking. They can act on various targets in the PNS, such as dopamine receptors and serotonin receptors. Examples include typical antipsychotics (e.g., haloperidol, chlorpromazine) and atypical antipsychotics (e.g., risperidone, olanzapine).
17. Mood stabilizers: These drugs are used to treat mood disorders, such as bipolar disorder or major depressive disorder. They can act on various targets in the PNS, such as sodium channels and GABA receptors. Examples include lithium, valproic acid, and carbamazepine.
18. Stimulants: These drugs are used to treat attention deficit hyperactivity disorder (ADHD) or narcolepsy. They can act on various targets in the PNS, such as dopamine transporters and norepinephrine transporters. Examples include amphetamine, methylphenidate, and modafinil.
19. Antihistamines: These drugs are used to treat allergies or symptoms of the common cold. They can act on various targets in the PNS, such as histamine receptors and muscarinic acetylcholine receptors. Examples include diphenhydramine, loratadine, and cetirizine.
20. Antiemetics: These

The Respiratory System is a complex network of organs and tissues that work together to facilitate the process of breathing, which involves the intake of oxygen and the elimination of carbon dioxide. This system primarily includes the nose, throat (pharynx), voice box (larynx), windpipe (trachea), bronchi, bronchioles, lungs, and diaphragm.

The nostrils or mouth take in air that travels through the pharynx, larynx, and trachea into the lungs. Within the lungs, the trachea divides into two bronchi, one for each lung, which further divide into smaller tubes called bronchioles. At the end of these bronchioles are tiny air sacs known as alveoli where the exchange of gases occurs. Oxygen from the inhaled air diffuses through the walls of the alveoli into the bloodstream, while carbon dioxide, a waste product, moves from the blood to the alveoli and is exhaled out of the body.

The diaphragm, a large muscle that separates the chest from the abdomen, plays a crucial role in breathing by contracting and relaxing to change the volume of the chest cavity, thereby allowing air to flow in and out of the lungs. Overall, the Respiratory System is essential for maintaining life by providing the body's cells with the oxygen needed for metabolism and removing waste products like carbon dioxide.

I'm sorry for any confusion, but "Sensory System Agents" is not a widely recognized or established medical term. Sensory systems refer to the parts of the nervous system that process and transmit information about the world around us, including the senses of sight, hearing, touch, taste, and smell. However, there are no specific "agents" that are generally recognized as being solely dedicated to affecting these systems in a medical context.

If you're referring to specific pharmaceutical agents or drugs that affect sensory systems, these would be more accurately described using terms related to the specific system (like "ophthalmic agents" for vision, or "anesthetics" for touch/pain) and the specific drug class or mechanism of action.

If you have a more specific context in mind, I'd be happy to try to provide a more targeted answer!

Central nervous system (CNS) agents are drugs or substances that act on the central nervous system, which includes the brain and spinal cord. These agents can affect the CNS in various ways, depending on their specific mechanism of action. They may be used for therapeutic purposes, such as to treat medical conditions like pain, anxiety, seizures, or sleep disorders, or they may be abused for their psychoactive effects.

CNS agents can be broadly classified into several categories based on their primary site of action and the nature of their effects. Some common categories of CNS agents include:

1. Depressants: These drugs slow down the activity of the CNS, leading to sedative, hypnotic, or anxiolytic effects. Examples include benzodiazepines, barbiturates, and sleep aids like zolpidem.
2. Stimulants: These drugs increase the activity of the CNS, leading to alertness, energy, and improved concentration. Examples include amphetamines, methylphenidate, and caffeine.
3. Analgesics: These drugs are used to treat pain and can act on various parts of the nervous system, including the peripheral nerves, spinal cord, and brain. Examples include opioids (such as morphine and oxycodone), non-opioid analgesics (such as acetaminophen and ibuprofen), and adjuvant analgesics (such as antidepressants and anticonvulsants).
4. Antiepileptics: These drugs are used to treat seizure disorders and work by modulating the electrical activity of neurons in the brain. Examples include phenytoin, carbamazepine, valproic acid, and lamotrigine.
5. Antipsychotics: These drugs are used to treat psychosis, schizophrenia, and other mental health disorders by blocking dopamine receptors in the brain. Examples include haloperidol, risperidone, and clozapine.
6. Antidepressants: These drugs are used to treat depression and anxiety disorders by modulating neurotransmitter activity in the brain. Examples include selective serotonin reuptake inhibitors (SSRIs) like fluoxetine and sertraline, tricyclic antidepressants like amitriptyline, and monoamine oxidase inhibitors (MAOIs) like phenelzine.
7. Anxiolytics: These drugs are used to treat anxiety disorders and work by modulating the activity of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain. Examples include benzodiazepines like diazepam and alprazolam, and non-benzodiazepine anxiolytics like buspirone.
8. Stimulants: These drugs are used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy by increasing the activity of dopamine and norepinephrine in the brain. Examples include methylphenidate, amphetamine salts, and modafinil.
9. Sedative-hypnotics: These drugs are used to treat insomnia and other sleep disorders by depressing the activity of the central nervous system. Examples include benzodiazepines like triazolam and zolpidem, and non-benzodiazepine sedative-hypnotics like eszopiclone and ramelteon.
10. Antipsychotics: These drugs are used to treat psychotic disorders like schizophrenia, bipolar disorder, and major depressive disorder by blocking the activity of dopamine in the brain. Examples include typical antipsychotics like haloperidol and chlorpromazine, and atypical antipsychotics like risperidone and aripiprazole.
11. Antidepressants: These drugs are used to treat depression and anxiety disorders by increasing the activity of serotonin, norepinephrine, or dopamine in the brain. Examples include selective serotonin reuptake inhibitors (SSRIs) like fluoxetine and sertraline, tricyclic antidepressants like amitriptyline, and monoamine oxidase inhibitors (MAOIs) like phenelzine.
12. Anticonvulsants: These drugs are used to treat seizure disorders like epilepsy, as well as chronic pain and bipolar disorder. They work by stabilizing the electrical activity of the brain. Examples include valproic acid, lamotrigine, and carbamazepine.
13. Anxiolytics: These drugs are used to treat anxiety disorders by reducing anxiety and promoting relaxation. Examples include benzodiazepines like diazepam and alprazolam, and non-benzodiazepine anxiolytics like buspirone.
14. Hypnotics: These drugs are used to treat insomnia and other sleep disorders by promoting sleep. Examples include benzodiazepines like triazolam and temazepam, and non-benzodiazepine hypnotics like zolpidem and eszopiclone.
15. Stimulants: These drugs are used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy by increasing alertness and focus. Examples include amphetamine salts, methylphenidate, and modafinil.
16. Antihistamines: These drugs are used to treat allergies and allergic reactions by blocking the activity of histamine, a chemical that is released during an allergic response. Examples include diphenhydramine, loratadine, and cetirizine.
17. Antipsychotics: These drugs are used to treat psychosis, schizophrenia, bipolar disorder, and other mental health conditions by reducing the symptoms of these conditions. Examples include risperidone, olanzapine, and quetiapine.
18. Antidepressants: These drugs are used to treat depression, anxiety disorders, and some chronic pain conditions by increasing the levels of certain neurotransmitters in the brain. Examples include selective serotonin reuptake inhibitors (SSRIs) like fluoxetine and sertraline, and tricyclic antidepressants like amitriptyline and imipramine.
19. Anticonvulsants: These drugs are used to treat seizure disorders and some chronic pain conditions by stabilizing the electrical activity of the brain. Examples include valproic acid, lamotrigine, and carbamazepine.
20. Muscle relaxants: These drugs are used to treat muscle spasms and pain by reducing muscle tension. Examples include cyclobenzaprine, methocarbamol, and baclofen.

Lung compliance is a measure of the ease with which the lungs expand and is defined as the change in lung volume for a given change in transpulmonary pressure. It is often expressed in units of liters per centimeter of water (L/cm H2O). A higher compliance indicates that the lungs are more easily distensible, while a lower compliance suggests that the lungs are stiffer and require more force to expand. Lung compliance can be affected by various conditions such as pulmonary fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), and chronic obstructive pulmonary disease (COPD).

Respiratory mechanics refers to the biomechanical properties and processes that involve the movement of air through the respiratory system during breathing. It encompasses the mechanical behavior of the lungs, chest wall, and the muscles of respiration, including the diaphragm and intercostal muscles.

Respiratory mechanics includes several key components:

1. **Compliance**: The ability of the lungs and chest wall to expand and recoil during breathing. High compliance means that the structures can easily expand and recoil, while low compliance indicates greater resistance to expansion and recoil.
2. **Resistance**: The opposition to airflow within the respiratory system, primarily due to the friction between the air and the airway walls. Airway resistance is influenced by factors such as airway diameter, length, and the viscosity of the air.
3. **Lung volumes and capacities**: These are the amounts of air present in the lungs during different phases of the breathing cycle. They include tidal volume (the amount of air inspired or expired during normal breathing), inspiratory reserve volume (additional air that can be inspired beyond the tidal volume), expiratory reserve volume (additional air that can be exhaled beyond the tidal volume), and residual volume (the air remaining in the lungs after a forced maximum exhalation).
4. **Work of breathing**: The energy required to overcome the resistance and elastic forces during breathing. This work is primarily performed by the respiratory muscles, which contract to generate negative intrathoracic pressure and expand the chest wall, allowing air to flow into the lungs.
5. **Pressure-volume relationships**: These describe how changes in lung volume are associated with changes in pressure within the respiratory system. Important pressure components include alveolar pressure (the pressure inside the alveoli), pleural pressure (the pressure between the lungs and the chest wall), and transpulmonary pressure (the difference between alveolar and pleural pressures).

Understanding respiratory mechanics is crucial for diagnosing and managing various respiratory disorders, such as chronic obstructive pulmonary disease (COPD), asthma, and restrictive lung diseases.

Respiratory physiological phenomena refer to the various mechanical, chemical, and biological processes and functions that occur in the respiratory system during breathing and gas exchange. These phenomena include:

1. Ventilation: The movement of air into and out of the lungs, which is achieved through the contraction and relaxation of the diaphragm and intercostal muscles.
2. Gas Exchange: The diffusion of oxygen (O2) from the alveoli into the bloodstream and carbon dioxide (CO2) from the bloodstream into the alveoli.
3. Respiratory Mechanics: The physical properties and forces that affect the movement of air in and out of the lungs, such as lung compliance, airway resistance, and chest wall elasticity.
4. Control of Breathing: The regulation of ventilation by the central nervous system through the integration of sensory information from chemoreceptors and mechanoreceptors in the respiratory system.
5. Acid-Base Balance: The maintenance of a stable pH level in the blood through the regulation of CO2 elimination and bicarbonate balance by the respiratory and renal systems.
6. Oxygen Transport: The binding of O2 to hemoglobin in the red blood cells and its delivery to the tissues for metabolic processes.
7. Defense Mechanisms: The various protective mechanisms that prevent the entry and colonization of pathogens and foreign particles into the respiratory system, such as mucociliary clearance, cough reflex, and immune responses.

Airway resistance is a measure of the opposition to airflow during breathing, which is caused by the friction between the air and the walls of the respiratory tract. It is an important parameter in respiratory physiology because it can affect the work of breathing and gas exchange.

Airway resistance is usually expressed in units of cm H2O/L/s or Pa·s/m, and it can be measured during spontaneous breathing or during forced expiratory maneuvers, such as those used in pulmonary function testing. Increased airway resistance can result from a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), bronchitis, and bronchiectasis. Decreased airway resistance can be seen in conditions such as emphysema or after a successful bronchodilator treatment.

Respiratory system abnormalities refer to any conditions or structures that do not function properly or are outside the normal range in the respiratory system. The respiratory system is responsible for taking in oxygen and expelling carbon dioxide through the process of breathing. It includes the nose, throat (pharynx), voice box (larynx), windpipe (trachea), bronchi, bronchioles, alveoli, and muscles and nerves that support breathing.

Respiratory system abnormalities can be congenital or acquired. Congenital abnormalities are present at birth and may include conditions such as cystic fibrosis, pulmonary hypoplasia, and congenital diaphragmatic hernia. Acquired abnormalities can develop at any time throughout a person's life due to various factors such as infections, injuries, environmental exposures, or aging. Examples of acquired respiratory system abnormalities include chronic obstructive pulmonary disease (COPD), asthma, pneumonia, lung cancer, and sleep apnea.

Respiratory system abnormalities can cause a range of symptoms, including coughing, wheezing, shortness of breath, chest pain, and fatigue. Treatment for respiratory system abnormalities depends on the specific condition and severity and may include medications, breathing treatments, surgery, or lifestyle changes.

Lung volume measurements are clinical tests that determine the amount of air inhaled, exhaled, and present in the lungs at different times during the breathing cycle. These measurements include:

1. Tidal Volume (TV): The amount of air inhaled or exhaled during normal breathing, usually around 500 mL in resting adults.
2. Inspiratory Reserve Volume (IRV): The additional air that can be inhaled after a normal inspiration, approximately 3,000 mL in adults.
3. Expiratory Reserve Volume (ERV): The extra air that can be exhaled after a normal expiration, about 1,000-1,200 mL in adults.
4. Residual Volume (RV): The air remaining in the lungs after a maximal exhalation, approximately 1,100-1,500 mL in adults.
5. Total Lung Capacity (TLC): The total amount of air the lungs can hold at full inflation, calculated as TV + IRV + ERV + RV, around 6,000 mL in adults.
6. Functional Residual Capacity (FRC): The volume of air remaining in the lungs after a normal expiration, equal to ERV + RV, about 2,100-2,700 mL in adults.
7. Inspiratory Capacity (IC): The maximum amount of air that can be inhaled after a normal expiration, equal to TV + IRV, around 3,500 mL in adults.
8. Vital Capacity (VC): The total volume of air that can be exhaled after a maximal inspiration, calculated as IC + ERV, approximately 4,200-5,600 mL in adults.

These measurements help assess lung function and identify various respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and restrictive lung diseases.

Functional Residual Capacity (FRC) is the volume of air that remains in the lungs after normal expiration during quiet breathing. It represents the sum of the residual volume (RV) and the expiratory reserve volume (ERV). The FRC is approximately 2.5-3.5 liters in a healthy adult. This volume of air serves to keep the alveoli open and maintain oxygenation during periods of quiet breathing, as well as providing a reservoir for additional ventilation during increased activity or exercise.

A lung is a pair of spongy, elastic organs in the chest that work together to enable breathing. They are responsible for taking in oxygen and expelling carbon dioxide through the process of respiration. The left lung has two lobes, while the right lung has three lobes. The lungs are protected by the ribcage and are covered by a double-layered membrane called the pleura. The trachea divides into two bronchi, which further divide into smaller bronchioles, leading to millions of tiny air sacs called alveoli, where the exchange of gases occurs.

Tidal volume (Vt) is the amount of air that moves into or out of the lungs during normal, resting breathing. It is the difference between the volume of air in the lungs at the end of a normal expiration and the volume at the end of a normal inspiration. In other words, it's the volume of each breath you take when you are not making any effort to breathe more deeply.

The average tidal volume for an adult human is around 500 milliliters (ml) per breath, but this can vary depending on factors such as age, sex, size, and fitness level. During exercise or other activities that require increased oxygen intake, tidal volume may increase to meet the body's demands for more oxygen.

Tidal volume is an important concept in respiratory physiology and clinical medicine, as it can be used to assess lung function and diagnose respiratory disorders such as chronic obstructive pulmonary disease (COPD) or asthma.

Medical Definition of Respiration:

Respiration, in physiology, is the process by which an organism takes in oxygen and gives out carbon dioxide. It's also known as breathing. This process is essential for most forms of life because it provides the necessary oxygen for cellular respiration, where the cells convert biochemical energy from nutrients into adenosine triphosphate (ATP), and releases waste products, primarily carbon dioxide.

In humans and other mammals, respiration is a two-stage process:

1. Breathing (or external respiration): This involves the exchange of gases with the environment. Air enters the lungs through the mouth or nose, then passes through the pharynx, larynx, trachea, and bronchi, finally reaching the alveoli where the actual gas exchange occurs. Oxygen from the inhaled air diffuses into the blood, while carbon dioxide, a waste product of metabolism, diffuses from the blood into the alveoli to be exhaled.

2. Cellular respiration (or internal respiration): This is the process by which cells convert glucose and other nutrients into ATP, water, and carbon dioxide in the presence of oxygen. The carbon dioxide produced during this process then diffuses out of the cells and into the bloodstream to be exhaled during breathing.

In summary, respiration is a vital physiological function that enables organisms to obtain the necessary oxygen for cellular metabolism while eliminating waste products like carbon dioxide.

Air sacs, also known as alveoli, are tiny air-filled sacs in the lungs where the exchange of oxygen and carbon dioxide occurs during respiration. They are a part of the respiratory system in mammals and birds. In humans, the lungs contain about 300 million alveoli, which are clustered together in small groups called alveolar sacs. The walls of the air sacs are extremely thin, allowing for the easy diffusion of oxygen and carbon dioxide between the air in the sacs and the blood in the capillaries that surround them.

Artificial respiration is an emergency procedure that can be used to provide oxygen to a person who is not breathing or is breathing inadequately. It involves manually forcing air into the lungs, either by compressing the chest or using a device to deliver breaths. The goal of artificial respiration is to maintain adequate oxygenation of the body's tissues and organs until the person can breathe on their own or until advanced medical care arrives. Artificial respiration may be used in conjunction with cardiopulmonary resuscitation (CPR) in cases of cardiac arrest.

Air pressure, also known as atmospheric pressure, is the force exerted by the weight of air in the atmosphere on a surface. It is measured in units such as pounds per square inch (psi), hectopascals (hPa), or inches of mercury (inHg). The standard atmospheric pressure at sea level is defined as 101,325 Pa (14.7 psi/1013 hPa/29.92 inHg). Changes in air pressure can be used to predict weather patterns and are an important factor in the study of aerodynamics and respiratory physiology.

Oscillometry is a non-invasive method to measure various mechanical properties of the respiratory system, including lung volumes and airway resistance. It involves applying small pressure oscillations to the airways and measuring the resulting flow or volume changes. The technique can be used to assess lung function in patients with obstructive or restrictive lung diseases, as well as in healthy individuals. Oscillometry is often performed during tidal breathing, making it a comfortable method for both children and adults who may have difficulty performing traditional spirometry maneuvers.

Respiratory Function Tests (RFTs) are a group of medical tests that measure how well your lungs take in and exhale air, and how well they transfer oxygen and carbon dioxide into and out of your blood. They can help diagnose certain lung disorders, measure the severity of lung disease, and monitor response to treatment.

RFTs include several types of tests, such as:

1. Spirometry: This test measures how much air you can exhale and how quickly you can do it. It's often used to diagnose and monitor conditions like asthma, chronic obstructive pulmonary disease (COPD), and other lung diseases.
2. Lung volume testing: This test measures the total amount of air in your lungs. It can help diagnose restrictive lung diseases, such as pulmonary fibrosis or sarcoidosis.
3. Diffusion capacity testing: This test measures how well oxygen moves from your lungs into your bloodstream. It's often used to diagnose and monitor conditions like pulmonary fibrosis, interstitial lung disease, and other lung diseases that affect the ability of the lungs to transfer oxygen to the blood.
4. Bronchoprovocation testing: This test involves inhaling a substance that can cause your airways to narrow, such as methacholine or histamine. It's often used to diagnose and monitor asthma.
5. Exercise stress testing: This test measures how well your lungs and heart work together during exercise. It's often used to diagnose lung or heart disease.

Overall, Respiratory Function Tests are an important tool for diagnosing and managing a wide range of lung conditions.

Positive-pressure respiration is a type of mechanical ventilation where positive pressure is applied to the airway and lungs, causing them to expand and inflate. This can be used to support or replace spontaneous breathing in patients who are unable to breathe effectively on their own due to conditions such as respiratory failure, neuromuscular disorders, or sedation for surgery.

During positive-pressure ventilation, a mechanical ventilator delivers breaths to the patient through an endotracheal tube or a tracheostomy tube. The ventilator is set to deliver a specific volume or pressure of air with each breath, and the patient's breathing is synchronized with the ventilator to ensure proper delivery of the breaths.

Positive-pressure ventilation can help improve oxygenation and remove carbon dioxide from the lungs, but it can also have potential complications such as barotrauma (injury to lung tissue due to excessive pressure), volutrauma (injury due to overdistention of the lungs), hemodynamic compromise (decreased blood pressure and cardiac output), and ventilator-associated pneumonia. Therefore, careful monitoring and adjustment of ventilator settings are essential to minimize these risks and provide safe and effective respiratory support.

Pulmonary ventilation, also known as pulmonary respiration or simply ventilation, is the process of moving air into and out of the lungs to facilitate gas exchange. It involves two main phases: inhalation (or inspiration) and exhalation (or expiration). During inhalation, the diaphragm and external intercostal muscles contract, causing the chest volume to increase and the pressure inside the chest to decrease, which then draws air into the lungs. Conversely, during exhalation, these muscles relax, causing the chest volume to decrease and the pressure inside the chest to increase, which pushes air out of the lungs. This process ensures that oxygen-rich air from the atmosphere enters the alveoli (air sacs in the lungs), where it can diffuse into the bloodstream, while carbon dioxide-rich air from the bloodstream in the capillaries surrounding the alveoli is expelled out of the body.

Respiratory tract diseases refer to a broad range of medical conditions that affect the respiratory system, which includes the nose, throat (pharynx), windpipe (trachea), bronchi, bronchioles, and lungs. These diseases can be categorized into upper and lower respiratory tract infections based on the location of the infection.

Upper respiratory tract infections affect the nose, sinuses, pharynx, and larynx, and include conditions such as the common cold, flu, sinusitis, and laryngitis. Symptoms often include nasal congestion, sore throat, cough, and fever.

Lower respiratory tract infections affect the trachea, bronchi, bronchioles, and lungs, and can be more severe. They include conditions such as pneumonia, bronchitis, and tuberculosis. Symptoms may include cough, chest congestion, shortness of breath, and fever.

Respiratory tract diseases can also be caused by allergies, irritants, or genetic factors. Treatment varies depending on the specific condition and severity but may include medications, breathing treatments, or surgery in severe cases.

Spirometry is a common type of pulmonary function test (PFT) that measures how well your lungs work. This is done by measuring how much air you can exhale from your lungs after taking a deep breath, and how quickly you can exhale it. The results are compared to normal values for your age, height, sex, and ethnicity.

Spirometry is used to diagnose and monitor certain lung conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory diseases that cause narrowing of the airways. It can also be used to assess the effectiveness of treatment for these conditions. The test is non-invasive, safe, and easy to perform.

"Locusta migratoria" is the scientific name for the migratory locust, which is a species of short-horned grasshopper. While it is not a medical term, I can provide some general information about this insect.

Migratory locusts are known for their ability to form large swarms that can travel long distances, consuming vast amounts of vegetation and causing significant damage to crops and pastures. They are native to Africa, Asia, and Europe but have been introduced to other parts of the world as well. The migratory locust is a agricultural pest and can pose a serious threat to food security in areas where they occur in large numbers.

From a medical perspective, some species of grasshoppers, including the migratory locust, can carry various pathogens that may affect humans and animals if ingested or come into contact with mucous membranes. However, there are no specific medical concerns associated with "Locusta migratoria" itself.

Pulmonary gas exchange is the process by which oxygen (O2) from inhaled air is transferred to the blood, and carbon dioxide (CO2), a waste product of metabolism, is removed from the blood and exhaled. This process occurs in the lungs, primarily in the alveoli, where the thin walls of the alveoli and capillaries allow for the rapid diffusion of gases between them. The partial pressure gradient between the alveolar air and the blood in the pulmonary capillaries drives this diffusion process. Oxygen-rich blood is then transported to the body's tissues, while CO2-rich blood returns to the lungs to be exhaled.

Phosgene is not a medical condition, but it is an important chemical compound with significant medical implications. Medically, phosgene is most relevant as a potent chemical warfare agent and a severe pulmonary irritant. Here's the medical definition of phosgene:

Phosgene (COCl2): A highly toxic and reactive gas at room temperature with a characteristic odor reminiscent of freshly cut hay or grass. It is denser than air, allowing it to accumulate in low-lying areas. Exposure to phosgene primarily affects the respiratory system, causing symptoms ranging from mild irritation to severe pulmonary edema and potentially fatal respiratory failure.

Inhaling high concentrations of phosgene can lead to immediate choking sensations, coughing, chest pain, and difficulty breathing. Delayed symptoms may include fever, cyanosis (bluish discoloration of the skin due to insufficient oxygen), and pulmonary edema (fluid accumulation in the lungs). The onset of these severe symptoms can be rapid or take up to 48 hours after exposure.

Medical management of phosgene exposure primarily focuses on supportive care, including administering supplemental oxygen, bronchodilators, and corticosteroids to reduce inflammation. In severe cases, mechanical ventilation may be necessary to maintain adequate gas exchange in the lungs.

Chemical warfare agents are defined as chemical substances that are intended or have the capability to cause death, injury, temporary incapacitation, or sensory irritation through their toxic properties when deployed in a military theater. These agents can be in gaseous, liquid, or solid form and are typically categorized based on their physiological effects. Common categories include nerve agents (e.g., sarin, VX), blister agents (e.g., mustard gas), choking agents (e.g., phosgene), blood agents (e.g., cyanide), and incapacitating agents (e.g., BZ). The use of chemical warfare agents is prohibited by international law under the Chemical Weapons Convention.

Mustard gas, also known as sulfur mustard or HS, is a chemical warfare agent that has been used in military conflicts. It is a viscous, oily liquid at room temperature with a garlic-like odor. Its chemical formula is (ClCH2CH2)2S.

Mustard gas can cause severe burns and blistering of the skin, eyes, and respiratory tract upon contact or inhalation. It can also damage the immune system and lead to serious, potentially fatal, systemic effects. The onset of symptoms may be delayed for several hours after exposure, making it difficult to recognize and treat the injury promptly.

Mustard gas is classified as a vesicant, which means it causes blistering or tissue damage upon contact with the skin or mucous membranes. It can also have long-term effects, including an increased risk of cancer and other health problems. The use of mustard gas in warfare is banned by international law under the Chemical Weapons Convention.

Chemical warfare is the use of chemicals in military conflict to incapacitate, injure, or kill enemy personnel or destroy equipment and resources. It involves the employment of toxic gases, liquids, or solids that have harmful effects on humans, animals, or plants. Chemical weapons can cause a wide range of symptoms, from temporary discomfort to permanent disability or death, depending on the type and amount of chemical used, as well as the duration and route of exposure.

Chemical warfare agents are classified into several categories based on their primary effects:

1. Nerve agents: These chemicals inhibit the enzyme acetylcholinesterase, which is essential for the proper functioning of the nervous system. Examples include sarin, tabun, soman, and VX. Exposure to nerve agents can cause symptoms such as muscle twitching, convulsions, respiratory failure, and death.
2. Blister agents: Also known as vesicants, these chemicals cause severe blistering and burns to the skin, eyes, and mucous membranes. Mustard gas is a well-known example of a blister agent. Exposure can lead to temporary or permanent blindness, respiratory problems, and scarring.
3. Choking agents: These chemicals cause damage to the lungs and respiratory system by irritating and inflaming the airways. Phosgene and chlorine are examples of choking agents. Symptoms of exposure include coughing, wheezing, shortness of breath, and potentially fatal lung edema.
4. Blood agents: These chemicals interfere with the body's ability to transport oxygen in the blood, leading to asphyxiation. Cyanide is a common example of a blood agent. Exposure can cause rapid heart rate, dizziness, headache, seizures, and death due to lack of oxygen.
5. Incapacitating agents: These chemicals are designed to temporarily disable or disorient enemy personnel without causing serious harm or death. Examples include riot control agents such as tear gas (CS) and pepper spray (OC). Exposure can cause symptoms such as coughing, sneezing, tears, and temporary blindness.

The use of chemical weapons in warfare is prohibited by several international treaties, including the Geneva Protocol and the Chemical Weapons Convention. Despite these bans, there have been numerous instances of their use throughout history, most notably during World War I and more recently in Syria's ongoing civil war.

Oximes are a class of chemical compounds that contain the functional group =N-O-, where two organic groups are attached to the nitrogen atom. In a clinical context, oximes are used as antidotes for nerve agent and pesticide poisoning. The most commonly used oxime in medicine is pralidoxime (2-PAM), which is used to reactivate acetylcholinesterase that has been inhibited by organophosphorus compounds, such as nerve agents and certain pesticides. These compounds work by forming a bond with the phosphoryl group of the inhibited enzyme, allowing for its reactivation and restoration of normal neuromuscular function.

Chlorofluorocarbons (CFCs) and methane are both greenhouse gases that contribute to global warming and climate change. However, they are distinct substances with different chemical structures and sources.

Chlorofluorocarbons (CFCs) are synthetic compounds made up of carbon, chlorine, and fluorine atoms. They were commonly used in refrigerants, aerosol sprays, and foam blowing agents until they were phased out due to their harmful effects on the ozone layer. CFCs have high global warming potential, meaning that they trap heat in the atmosphere many times more effectively than carbon dioxide.

Methane, on the other hand, is a naturally occurring gas made up of one carbon atom and four hydrogen atoms (CH4). It is produced by the decomposition of organic matter, such as in landfills, wetlands, and the digestive tracts of animals like cattle. Methane is also released during the extraction and transportation of fossil fuels like coal, oil, and natural gas. While methane has a shorter lifespan in the atmosphere than CFCs, it is an even more potent greenhouse gas, trapping heat at a rate 25 times greater than carbon dioxide over a 100-year period.

Therefore, while both CFCs and methane are harmful to the climate, they are distinct substances with different sources and impacts.

A blister is a small fluid-filled bubble that forms on the skin due to friction, burns, or contact with certain chemicals or irritants. Blisters are typically filled with a clear fluid called serum, which is a component of blood. They can also be filled with blood (known as blood blisters) if the blister is caused by a more severe injury.

Blisters act as a natural protective barrier for the underlying skin and tissues, preventing infection and promoting healing. It's generally recommended to leave blisters intact and avoid breaking them, as doing so can increase the risk of infection and delay healing. If a blister is particularly large or painful, medical attention may be necessary to prevent complications.

Respiratory-system-disorders; Physical-agents; Physiological-response; Mortality-data; Industrial-hazards; Carcinogens; ... Agents discussed include: methylene (bis(p- phenylisocyanate) (101688), carbon-monoxide (630080), methylene- chloride (75092), ... Topics of investigation included: respiratory diseases related to exposures in the workplace; effect of physical and behavioral ... agents on worker health and performance; effects of exposure to potential carcinogenic and other toxic agents; health effects ...
Categories: Respiratory System Agents Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
Respiratory System Agents / administration & dosage* * Respiratory System Agents / therapeutic use * Self Administration / ... 1 National Institute of TB and Respiratory Diseases (Erstwhile L.R.S Institute of TB and Respiratory Diseases), New Delhi, ... 2 National Institute of TB and Respiratory Diseases (Erstwhile L.R.S Institute of TB and Respiratory Diseases), New Delhi, ...
Respiratory Distress Syndrome / mortality * Respiratory Distress Syndrome / therapy* * Respiratory System Agents / therapeutic ... 36 +/- 9 mm Hg, p , .05). Minute ventilation, respiratory system compliance, physiologic deadspace, and PaCO2 remained ... and almitrine bismesylate on gas exchange and oxygen transport in acute respiratory distress syndrome Crit Care Med. 1997 May; ... could exert additive beneficial effects when used in combination in patients with severe acute respiratory distress syndrome ( ...
Ensure that workers wear appropriate PPE to preclude exposure to infectious agents or chemicals through the respiratory system ... system used to reprocess the endoscope (if more than one system could be used in the reprocessing area), and serial number or ... Severe Acute Respiratory Syndrome Coronavirus), or Bioterrorist Agents ... Inform each worker of the possible health effects of his or her exposure to infectious agents (e.g., hepatitis B virus [HBV], ...
... you may have a higher chance of developing strep throat and other respiratory infections. ... If cilia become paralyzed, particles and infectious agents are free to travel through your respiratory system. ... suggests that vaping and the use of e-cigarettes may also compromise your respiratory systems ability to fight off viruses and ... Its an activity that can weaken your immune system and cause throat irritation, factors that may promote respiratory ...
As a consequence, the respiratory immune system must differentiate harmless antigens and potentially harmful infectious agents ... These agents have received regulatory approval for asthma therapy and are the first new therapies to be licensed for asthma in ... In Progress in respiratory research: new drugs in asthma, allergy and COPD. Volume 31. T. Hansel and P. Barnes, editors. Karger ... Surprisingly, the model systems that have been used most frequently in studies designed to understand asthma pathogenesis have ...
Airborne infections usually land in the respiratory system, with the agent present in aerosols (infectious particles < 5 µm in ... Inhalation of these pathogens affects the respiratory system and can then spread to the rest of the body. Sinus congestion, ... The relevant infectious agent may be viruses, bacteria, or fungi, and they may be spread through breathing, talking, coughing, ... Respiratory droplets were thought to rapidly fall to the ground after emission: but smaller droplets and aerosols also contain ...
... and pathogenic agents that primarily target the human respiratory system. Previous outbreaks of severe acute respiratory ... and pathogenic agents that primarily target the human respiratory system. Previous outbreaks of severe acute respiratory ... AntimalarialsAntiviral AgentsCOVID-19COVID-19 VaccinesChinaHumansImmunization, PassivePandemicsSARS-CoV-2United StatesCOVID-19 ... syndrome-CoV and Middle East respiratory syndrome-CoV remain life-threatening and global public health concerns. A novel CoV ...
Although CX is often grouped with the vesicant chemical warfare agents, it is not a true vesicant because it does not cause ... is an urticant or nettle agent that causes a corrosive type of skin and tissue injury. ... It primarily affects the skin, eyes, respiratory system, and gastrointestinal tract. The agent seems to cause its greatest ... Exposures to CX result from its deliberate use as a chemical warfare agent. [3, 6, 9] Since this chemical has no useful ...
People who breathe in vapors of Lewisite or Mustard-Lewisite may experience damage to the respiratory system. Contact with the ... Blister agents Lewisite and Mustard-Lewisite have not been found in any of the 1,585 National Priorities List sites identified ... It is unlikely that the general population will be exposed to blister agents Lewisite or Mustard-Lewisite. ... People who breathe in vapors of Lewisite or Mustard-Lewisite may experience damage to the respiratory system. Contact with the ...
Helps to protect the face, eyes and respiratory system against chemicals and radioactive and biological warfare agents. -The ... eyes and respiratory system against chemicals and radioactive and biological warfare agents in the form of gases, vapors, ...
Being connected to the throat, it is said to strengthen and balance the respiratory system by acting as an antiseptic agent. ... White is the color of these stones, which stands for the purity of the entire energy system. It awakens creativity and boosts ... In Hinduism, all nine gemstones are connected with the Navagrahas or nine planets of the Solar system. ... It is beneficial for the treatment of skeletal and nervous system disorders along with cancerous conditions. ...
Respiratory System Agents Antidote Blood System Agents Feed Grade Vitamins Anesthetic Agents Anti-Allergic Agents ... Antineoplastic Agents Antiparasitic Agents Other see more less Usage. Animal Pharmaceuticals see more less Efficacy. Promote ...
Respiratory System Agents. *Palivizumab. *Infant, Newborn. *Infant. *Humans. *Guidelines as Topic. *Evidence-Based Medicine ...
... and other agents affecting the respiratory system.. *Any dysfunction, including signs and symptoms of respiratory disease, ... BSL-3 laboratory workers (select agents). Employees who have access to select agents or who work in a biosafety level 3 (BSL-3 ... Respiratory protection. Individuals who wear respiratory protective devices must be medically evaluated prior to wearing a ... A physical examination with particular emphasis on the respiratory system.. *A chest X-ray is interpreted and classified ...
The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with ... Agents that pose a particularly high risk to humans are classified as Tier 1 Select Agents; Bacillus anthracis is a Tier 1 ... Possession, use and transfer of select agents and toxins; biennial review of the list of select agents and toxins and enhanced ... Bactericidal action of formalin on the causative agent of plague] [in Russian]. Arkh Patol. 1979;41:80-2.PubMedGoogle Scholar ...
Certain chemicals used to flavor vape products may damage the respiratory system and lungs. ... There may be a risk of respiratory illnesses from using vape products. ... E-cigarette emissions are filled with toxic chemicals - from compounds in weed killers to cancer-causing agents - that harm the ... Legal Help for Vaping Respiratory Problems. Vaping harms the respiratory system - countless studies and numerous ...
... chemical agent - Sharing our stories on preparing for and responding to public health events ... The gas sends your nervous system into overdrive. You begin having convulsions. EMTs rush to the scene while you go into ... respiratory Read More ,. Posted on February 19, 2015. by Blog Administrator18 Comments. Categories General, PHPR: Health ... an enclosed crowded place-perhaps a subway or a mall-and a terrorist organization releases lethal quantities of a nerve agent ...
33622600 - Beta-blocking agents. 33670000 - Medicinal products for the respiratory system. 33651520 - Immunoglobulins. 33661200 ... 33694000 - Diagnostic agents. 33661000 - Medicinal products for the nervous system. 33662100 - Ophthalmologicals. 33651100 - ... 33661700 - Other nervous system medicinal products. 33181100 - Haemodialysis devices. 33190000 - Miscellaneous medical devices ... 33621100 - Antithrombotic agents. 33674000 - Cough and cold preparations. 33642100 - Pituitary, hypothalamic hormones and ...
However, under the same nicotine dosage, the harm of e-cigarette aerosol to the respiratory system is less than that of ... The study found that although both e-cigarettes and traditional cigarettes are harmful to the respiratory system, the harm of e ... Chinese Research Team Finds: E-cigarettes have less impact on respiratory system than traditional cigarettes. ... suggesting that there may be lesions in the respiratory system. In contrast, the lung coefficient of mice exposed to e- ...
... central nervous system depressants, and agents with potential for causing respiratory depression (e.g., opiates). ... Use of these agents should be optimized in elderly patients, patients with multiple comorbidities, patients with liver disease ... Use of these agents should be closely monitored and optimized in patients receiving other sedating medications, ... The treatment options and their use in the situations described below are also based on clinical experience with these agents ...
Weight-loss practices and asthma: findings from the behavioral risk factor surveillance system. Obes Res 2003;11:81-86. ... Influence of body mass index on the response to asthma controller agents. M. Peters-Golden, A. Swern, S. S. Bird, C. M. Hustad ... Your Name) has sent you a message from European Respiratory Society Message Body (Your Name) thought you would like to see the ... European Respiratory Society. 442 Glossop Road. Sheffield S10 2PX. United Kingdom. Tel: +44 114 2672860. Email: journals@ersnet ...
Phosgene (CG): A choking agent, phosgene gas causes damage to the respiratory system leading to fluid build-up in the lungs. ... Nerve agent A nerve agent is a chemical weapon that attacks the human nervous system, leading to uncontrolled nerve cell ... Choking agent Choking agent: A chemical weapon which attacks lung tissue when inhaled, leading to respiratory failure. Choking ... Blood agent Blood agents are chemical agents that enter the victims blood and disrupt the bodys use of oxygen. Arsenic-based ...
More deep sequencing studies are needed to explore the microbial variation in the respiratory system in connection with TB. ... Therefore, the aim of the present analysis was to estimate the relative proportion of respiratory microbiota at phylum and ... The composition of the respiratory microbiota in TB patients and healthy controls were quite different. ... Previous studies demonstrated that the diversity and composition of respiratory microbiota in TB patients were different from ...
... and fungal agents from the building environment and carries them into a persons respiratory system. Another potential problem ... o The respiratory systems capacity to take in and exhale oxy- gen may be reduced. o There may be an increased susceptibility ... o Install an alarm system to warn of power failures that would affect the mechanical ventilation system. Check and maintain the ... and dried manure on floors and animals can irritate respiratory systems. The severity of these problems is seasonal in that the ...
... how can everything in our upper respiratory system be associated with agent orange?/But everything below the waste doesnt ... We had no on board propulsion system and were unable to maneuver. We were a big fat sitting duck.. As a radioman my duties were ... Im sorry but the Va is doing a good job with the determination of illnesses as a result of exposure to agent orange. There is ... What gets me is the hard time we as veterans are receiving in applying for agent orange disabilities, I have been told the ship ...
Hyperpnea (increased respiratory rate/depth) - early (increased respiratory rate/depth). *Bradypnea (decreased respiratory rate ... thereby leading to an accumulation of acetylcholine in the central and peripheral nervous system. Excess acetylcholine produces ... Nerve agentsplus icon *Case Definition: Nerve Agents or Organophosphates. *Toxic Syndrome Description: Nerve Agent and ... Nerve agents are chemical warfare agents that have the same mechanism of action as OP organophosphate pesticides insecticides. ...
Commercial products frequently combine these agents and may include modified-live parvovirus and leptospiral antigens. An ... It often occurs in dogs already affected by respiratory disease... read more and cats Tracheobronchitis (Bronchitis, Bronchial ... Dogs commonly exhibit systemic clinical signs (fever, lethargy, loss of appetite), respiratory... read more . Canine reoviruses ... It is more likely to occur in cats already affected by respiratory... read more . ...

No FAQ available that match "respiratory system agents"